Long-Term Administration of Calcium Acetate Efficiently Controls Severe Hyperphosphataemia in Haemodialysis Patients

Hess, B.; Binswanger, U. (1990). Long-Term Administration of Calcium Acetate Efficiently Controls Severe Hyperphosphataemia in Haemodialysis Patients. Nephrology, dialysis, transplantation, 5(8), pp. 630-632. Oxford University Press 10.1093/ndt/5.8.630

Preview

Text 5-8-630.pdf - Published Version Available under License Publisher holds Copyright. Download (244kB) | Preview

In order to avoid aluminium toxicity, calciumcontaining phosphate binders have been used increasingly. Unfortunately, calcium carbonate and calcium citrate produce hypercalcaemia in a number of patients. New studies have shown that calcium acetate is promising in that it binds more phosphate than calcium carbonate at comparable doses. We tested calcium acetate in eight severely hyperphosphataemic patients (2.25 ± 0.08 mmol/l) on maintenance haemodialysis over 5 months. Serum phosphate decreased to 1.86 ± 0.06 mmol/l, but at the cost of an increase in serum calcium. However, the increment of serum calcium was always less than the respective decrease of serum phosphate, and hypercalcaemia—immediately reversible after dose reduction—only occurred once in two patients.

Interest & Impact

Downloads

133 since deposited on 07 Sep 2020
18 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item